Chanumolu Kiran Kumar, Nandhakumar Ramachandran^*

CMC-Computers, Materials & Continua, Vol.78, No.3, pp. 3151-3176, 2024, DOI:10.32604/cmc.2023.043534

Abstract Wireless Network security management is difficult because of the ever-increasing number of wireless network malfunctions, vulnerabilities, and assaults. Complex security systems, such as Intrusion Detection Systems (IDS), are essential due to the limitations of simpler security measures, such as cryptography and firewalls. Due to their compact nature and low energy reserves, wireless networks present a significant challenge for security procedures. The features of small cells can cause threats to the network. Network Coding (NC) enabled small cells are vulnerable to various types of attacks. Avoiding attacks and performing secure “peer” to “peer” data transmission is a challenging task in small… More >

JINNI MA^#, MEILIN ZHOU^#, XIN XU, XINYAO GAO, HAIXIA WANG, JINHUA SHEN, LU XUE^*

BIOCELL, Vol.48, No.2, pp. 239-252, 2024, DOI:10.32604/biocell.2023.045076

Abstract Background: Placenta specific 8 (PLAC8) is a candidate oncogene involved in the development and progression of solid tumors. However, the status of PLAC8 in lung cancer (LC), especially non-small cell lung cancer (NSCLC) is still not lucid. Methods: Tissue microarray analysis (TMA) was performed to detect the expression patterns of PLAC8 in LC tissues and cell lines. Then a series of cellular experiments were performed fto assess cell proliferation, cell cycle profiles, and cell motility to explore the role of PLAC8 in NSCLC-derived cell lines: H1299 and A549. Results: TMA results showed that PLAC8 played complex and even contradictory roles… More >

NAN TANG^1,#, YAJING ZHAN^1,#, JIAYAN MAO^2,#, ANKANG YIN¹, WEI WANG^3,*, JUAN WANG^3,*

BIOCELL, Vol.47, No.9, pp. 2009-2026, 2023, DOI:10.32604/biocell.2023.029269

Abstract Non-small cell lung cancer (NSCLC) is a malignant tumor with high incidence worldwide. Triptolide (TP), extracted from Tripterygium wilfordii Hook F, exhibits potent broad-spectrum antitumor activity. Although some mechanisms through which TP inhibits NSCLC are well understood, those that involve ribosomal proteins remain yet to be understood. In this study, the transcriptome and proteome were integrated and analyzed. Our data indicated ribosomal protein L4 (RPL4) to be a core hub protein in the protein-protein interaction network. RPL4 is overexpressed in NSCLC tissues and cells. Transfection with siRPL4 or TP treatment alone arrested the cell cycle in the G1 phase, induced… More > Graphic Abstract

WEI DU¹, FANG YIN¹, YATING ZHONG¹, MINJIE LUO¹, ZHEN WANG², PENG LIN², QING LIU^2,*, HAN YANG^2,*

Oncology Research, Vol.31, No.6, pp. 929-936, 2023, DOI:10.32604/or.2023.030611

Abstract Non-small cell lung cancer (NSCLC) is a highly lethal cancer, and better treatments are urgently needed. Many studies have implicated circular RNAs (circRNAs) in the progression of multiple malignant tumors. Nonetheless, the functions of circRNAs in NSCLC remain unclear. To study new targets for the treatment of NSCLC, circRNA expression profiling was performed on NSCLC tissues and para-carcinoma nonmalignant tissues. RNA was isolated and used for circRNA sequencing. Biological studies were performed in vitro and in vivo to determine the functions of circRNAs in NSCLC, including their functions in cell proliferation and migration. How circRNAs function in NSCLC was explored… More > Graphic Abstract

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >

SANDRA STICKLER¹, BARBARA RATH¹, MAXIMILIAN HOCHMAIR², CLEMENS LANG³, LUKAS WEIGL⁴, GERHARD HAMILTON^1,*

Oncology Research, Vol.31, No.1, pp. 13-22, 2023, DOI:10.32604/or.2022.027281

Abstract Small cell lung cancer (SCLC) is frequently disseminated and has a dismal prognosis with survival times of approximately two years. This cancer responds well to initial chemotherapy but recurs within a short time as a globally chemoresistant tumor. Circulating tumor cells (CTCs) are held responsible for metastasis, the extremely high numbers of these cells in advanced SCLC allowed us to establish several permanent CTC cell lines. These CTCs are distinguished by the spontaneous formation of large spheroids, termed tumorospheres, in regular tissue culture. These contain quiescent and hypoxic cells in their interior and are associated with high chemoresistance compared to… More >

Jiajian Shi¹, Yuchen Chen^1,*, Chentai Peng¹, Linwu Kuang², Zitong Zhang¹, Yangkai Li^2,*, Kun Huang¹

Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545

Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been well… More >

RUI ZHOU^#, JIANYANG XU^#, LINGWEI WANG^*, JIANXIN LI^*

Oncology Research, Vol.29, No.6, pp. 411-423, 2021, DOI:10.32604/or.2022.026236

Abstract Long noncoding RNAs (lncRNAs) act as key regulators controlling complex cellular behaviors in nonsmall cell lung cancer (NSCLC). We investigated the expression of lncRNA PRRT3 antisense RNA 1 (PRRT3-AS1) in paired samples of NSCLC and adjacent normal tissues from a patient cohort in our hospital using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and found that it was significantly higher in NSCLC tissue than in normal tissue, consistent with The Cancer Genome Atlas database. Furthermore, functional investigation revealed that lncRNA PRRT3-AS1 depletion inhibited NSCLC-cell proliferation, colony formation, invasion, and migration, whereas its overexpression exerted the opposite effects. Moreover, PRRT3-AS1… More >

HUALIANG LV^1,#,*, CHANGCHUN LAI^2,#, WENQU ZHAO³, YIBO SONG¹

Oncology Research, Vol.29, No.6, pp. 401-409, 2021, DOI:10.32604/or.2022.025262

Abstract It has been certified that GABPB1-AS1 is aberrantly expressed and plays as a vital role in some kinds of cancers. However, its expression pattern and functions in non-small cell lung cancer (NSCLC) are still largely unknown. This study aims to assess GABPB1-AS1 expression and biological roles in NSCLC. The expression of GABPB1-AS1 was detected in NSCLC specimens and adjacent normal specimens. CCK8 and Transwell assays were performed to evaluate the effects of GABPB1-AS1 on NSCLC cell proliferation, migration and invasion. Bioinformatics tools and luciferase reporter assays were applied to predict and verify GABPB1-AS1’s direct targets. The results revealed that GABPB1-AS1… More >

Li Xu, Kang Li, Jia Li, Liyu Liu, Fang Xu, Yan Xu, Yi Kong, Xingxiang Pu, Qianzhi Wang, Jingyi Wang, Bolin Chen^*, Lin Wu^*

Oncologie, Vol.24, No.3, pp. 579-590, 2022, DOI:10.32604/oncologie.2022.022121

Abstract Background: Non-small cell lung cancer (NSCLC), caused by abnormal gene drive, may have primary drug resistance after treatment with tyrosine kinase inhibitors (EGFR-TKIs). Therefore, we explore whether the primary drug-resistant NSCLC treated with EGFR-TKI is related to the miR-21/Sonic Hedgehog (SHH)/PI3K/AKT pathway. Methods: The patients from our hospital who meet the AJCC TNM staging (7th edition) stage IIIB and stage IV NSCLC were selected in this case study. Thereafter, the treatment response of EGFR-TKIs was evaluated according to the solid tumor efficacy evaluation standard (version 1.1). The patients were divided into the EGFR-TKIs primary drug resistance group (EGFR-TKIs-Primary-R) and the… More >